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Background and Aims. Intraperitoneal chemotherapy is a basic tool in the treatment of peritoneal malignancy. The purpose of
the study is to investigate the eﬀect of adjuvant perioperative intraperitoneal chemotherapy in the treatment of locally advanced
colorectal cancer. Patients and Methods. Patients with T3 and T4 colorectal carcinomas that underwent R0 resection received either
hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC group = 40 patients) or early postoperative intraperitoneal
chemotherapy (EPIC group = 67 patients). The survival, the recurrences and the sites of recurrence were assessed. Results.T h e
3-year survival rate for HIPEC group was 100% and for EPIC group 69% (P = .011). Nodal inﬁltration was found to be the
single prognostic indicator of survival. The incidence of recurrence in EPIC group was higher than in HIPEC group (P = .009).
The independent indicators of recurrence were the use of HIPEC and the degree of diﬀerentiation (P<. 05). Conclusions.
Intraperitoneal chemotherapy, particularly HIPEC, as an adjuvant in locally advanced colorectal carcinomas appears to improve
survival and decrease the incidence of recurrence.
1.Introduction
The incidence of recurrence for Dukes’ B and C colorectal
carcinomas is approximately 50% [1]. The corner stone in
the surgical treatment of rectal cancer is total mesorectal
excision [2]. The incidence of locoregional recurrence has
been reduced signiﬁcantly by total mesorectal excision [3].
Similar to this approach, extensive lymph node resec-
tion has been questioned for colon cancer [4]. So far,
numerous adjuvant treatments have been used to prevent
the development of recurrence and improve survival [5].
Preoperative irradiation in rectal cancer has been shown
to signiﬁcantly reduce the incidence of locoregional recur-
rences [6], but only one study showed improvement of
survival [7]. Systemic chemotherapy has shown to improve
survival in stage III colon cancer [8]. Both irradiation
and systemic chemotherapy are followed by signiﬁcant
toxicity in contrast to intraperitoneal chemotherapy [8, 9].
Intraperitoneal chemotherapy integrated in cytoreductive
surgery is the standard treatment of peritoneal malignancy
that which survival by eradicating the microscopic residual
tumor [10]. Locoregional recurrence in locally advanced
gastrointestinal carcinomas is the result either of tumor
involving the serosa and perforation of the bowel wall or of
iatrogenic dissemination of cancer emboli which give rise to
locoregional tumor within 2-3 years [11]. If chemotherapy
is used by the intraperitoneal route, microscopic residual
tumor resulting from surgical manipulations in locally
advanced colorectal cancer surgery may possibly be eradi-
cated.
The purpose of the study is to investigate the eﬀect
of adjuvant perioperative intraperitoneal chemotherapy
after resection of locally advanced colorectal carcinomas.
Hyperthermic intraoperative intraperitoneal chemotherapy
(HIPEC) is compared with early postoperative intraperi-
toneal chemotherapy (EPIC). The end point of the study is
the investigationofoverall survival, recurrence rate, and sites
of recurrence.2 ISRN Surgery
2.PatientsandMethods
From 1999 to 2004 patients with locally advanced (T3,
T4) colorectal carcinomas were prospectively assigned to
undergo R0 resection and receive EPIC as an adjuvant. From
2005until todaypatientswith thesame tumorcharacteristics
were prospectively assigned to undergo R0 resection and
receive HIPEC as an adjuvant.
2.1. Eligibility Criteria. Patients meeting the following cri-
teria were eligible for treatment: (1) age over 18 years that
could undergo major surgery, (2) satisfactory cardiopul-
monary function with no evidence of myocardial infarction
during the previous 6 months, (3) normal liver function,
(4) normal renal function (blood urea < 50mg/dl and
creatinine level < 1.5mg/dl), (5) normal white blood cell
count (>4000) and platelets (>150.000), and (6) perfor-
mance status >50% according to Karnofsky performance
scale.
The exclusion criteria were the following: (1) age under
18 years, (2) the presence of irresectable metastatic disease,
(3) previous treatment for cancer, (4) the presence of a
second malignant tumor at high risk for recurrence (except
for skin basal cell carcinoma or in situ cervix carcinoma
radically treated), (5) Karnofsky performance status <50%,
(6) psychosis, drug or alcohol addiction, (7) the presence of
diﬀuse peritonitis, and (8) pregnancy.
2.2. Deﬁnitions and Diagnosis. Right colon was considered
the segment of the large bowel, proximal to the left colic
ﬂexure. Left colon was considered the segment of the large
bowel from the left colic ﬂexure distal to the peritoneal
reﬂexion. The rectum was considered the segment of the
large bowel, distal to the peritoneal reﬂexion.
The diagnosis of carcinoma was established by physical
examination, biochemical and hematological examinations,
tumormarkers(CEA,CA19-9,andCA-125),abdominaland
thoracic CT scan, whole-body bone scan, colonoscopy, and
tumor biopsy.
The protocols were approved by the ethical committee of
the hospitals and the patients signed informed consent.
2.3. Treatment. Samples for peritoneal cytology were taken
after abdominal exploration. Total mesorectal excision was
required for tumors of the middle and lower rectum. The
assessment of sphincter preservation was on the surgeon’s
judgment.
The Coliseum technique (open abdomninal method)
was used during HIPEC which was administered before
the reconstruction of the continuity of the alimentary tract
for 90min if mitomycin-C (15mg/m2) was used and for
60minifoxaliplatin(130mg/m2)wasused.The temperature
during perfusion was maintained at 42.5–43◦C. Oxaliplatin
or mitomycin-C was used according to surgeon’s preference.
Thecytostaticdrugwasdilutedin 2litersofnormalsaline for
HIPEC and in 1–1.5 liters of D1.5Wi fE P I Cw a su s e d .
EPIC was given through a Tenckhoﬀ catheter that was
positioned at the tumor bed for the ﬁrst 5 postoperative
days. The chemotherapy regimen was instilled rapidly in
the peritoneal cavity and dwelled for 23 hours. Then
the drains were opened for one hour, and instillation of
the regimen began again. 5-FU (600mg/m2)w i t h5 0 m e q
NaHCO3 was used for EPIC.
Allthepatientswho werepTNMstageIIIandIVreceived
additional 6 cycles of systemic chemotherapy with 5-FU +
leukovorine.
Right colon carcinomas were treated with right or
transverse colectomy depending on tumor location. Left
colon carcinomas were treated with left colectomy and rectal
tumors with low anterior resection or abdominoperineal
resection. A protective colostomy was always used if low
anterior resection was performed.
Toxicity was recorded from the time of operation and
during followup.
2.4. Histopathology. All the specimens were histopatholog-
ically examined. Details about T, N, TNM stage, degree
of diﬀerentiation, and circumferential margins of resection
were recorded.
2.5. Followup. Followup was possible every 4 months dur-
ing the ﬁrst year and every 6 months later by physical
examination, hematological and biochemical examinations,
tumor markers (CEA, CA 19-9, CA-125), thoracic and
abdominal CT scan, and whole-body bone scan whenever it
was indicated. Colonoscopy was performed once a year after
the ﬁrst year of followup. The recurrences and the sites of
recurrence were recorded.
2.6. Statistical Analysis. The proportions of patients with a
given characteristic were compared by chi-square analysis
or by Pearson’s test. Diﬀerences in the means of continuous
measurement were tested bytheStudent’st-test. The survival
curves were obtained using the Kaplan-Meier method, and
the comparison of curves was calculated using the log-
rank test. Cox regression analysis made multiple analysis of
survival possible. Logistic regression analysis made multiple
analysis of recurrence, morbidity, and mortality possible. A
two-tailed P value <.05 was considered statistically signiﬁ-
cant.
3.Results
The HIPEC-group consisted of 45 patients and the EPIC
group of 63 patients. Five patients from the HIPEC-group
and 6 patients from the EPIC group were rejected from
the analysis because they were found to have pT2N0M0
tumors or they had peritoneal malignancy. The groups were
comparable for age, gender, T stage, nodal status, TNM
stage, anatomic distribution of the tumor, type of surgical
operation, morbidity, and sites of recurrence. They were
diﬀerentinperformance status,degreeofdiﬀerentiation,and
recurrence (Table 1). In 2 patients of HIPEC-group, liver
metastatic disease was detected intraoperatively. The lesions
were completely resected, and the patients were included
in the study protocol. All the surgical operations were R0
resections. All the samples for peritoneal cytology were
negative for malignant cells.ISRN Surgery 3
Table 1: General characteristics.
Variable HIPEC EPIC P value
Mean age 67 ±13.2 (25–84) 70.9 ± 9.9 (38–92) >.05
M/F ratio 25/15 33/24 >.05
Performance status
90–100%/70–80%/50–60% 22/15/3 52/5/0 <.001
T( T 3/T4) 35/15 50/7 >.05
N( N 0/N1/N2) 20/14/6 31/15/11 >.05
Stage (II/III/IV) 19/19/2 31/26/0 >.05
G( G 1/G2/G3) 11/25/4 3/49/5 .006
Anatomic distribution
>.05 Right colon 15 19




Right colectomy 15 16
Transverse colectomy 0 3
Left colectomy 9 22
Low anterior resection 10 8
Abdominoperineal resection 6 8
Hospital mortality 1 9 .009
Morbidity 16 22 >.05
Recurrence 1 16 .001
Pattern of recurrence
Distant/locoregional 1/0 12/4 >.05
3.1. Morbidity and Hospital Mortality. EPIC was found to
be related to hospital mortality (P = .034) but it did not
inﬂuence the survival independently. The hospital mortality
was 10.3%. Only one patient in HIPEC-group died in
the immediate postoperative period (Table 1). The overall
morbidity rate was 39.2%. The postoperative complications
are listed in Table 2.N oc l i n i c a lv a r i a b l ew a sf o u n dt ob e
related to morbidity.
3.2. Survival. T h e3 - y e a rs u r v i v a lr a t ef o rt h eH I P E C - g r o u p
was 100%. For EPIC group mean survival was 100 ± 6
months, and 3-year survival rate was 69% (P = .011)
(Figure 1). Nodal status was also found to be related to
survival (P = .0262). Multivariate analysis of survival
showed that only nodal status was a prognostic indicator of
survival (HR = 5.221, P = .022, 95% CI = 1.118–4.182).
3.3. Followup. The median followup time for HIPEC and
EPIC group was 17 and 28 months, respectively. During
followup, one patient (2.5%) in the HIPEC-group was
recorded with recurrence and 16 (28%) patients in the EPIC
group (P = .009). The patient in the HIPEC-group had
colon cancer and developed liver metastasis. In the EPIC
group3 patientswith rectal cancerdevelopedrecurrence and
only one of them locoregional. Perioperative intraperitoneal
chemotherapy (P = .001) and the degree of diﬀerentiation
(P = .024) were found to be related to recurrence. By
multivariate analysis the degree of diﬀerentiation (HR =
5.658, P = .017, 95% CI = .006–.516) and the use of
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Figure 1: Survival according to type of intraperitoneal chemother-
apy (continuous line-HIPEC-group, dotted line = EPIC group).
intraperitoneal chemotherapy (HR = 6.663, P = .001, 95%
CI = .008–.519) were found to be prognostic indicators for
the development of recurrence.4 ISRN Surgery
Table 2: Postoperative complications.
Complication HIPEC EPIC Total Total %
Anastomotic failure 4 4 8 8.2
Respiratory 3 5 8 8.2
Wound infection 4 1 5 5.2
Enterocutaneous ﬁstula 2 2 4 4.1
Sepsis 1 2 3 3.1
Cardiovascular 0 2 2 2.1
Acute renal failure 1 2 3 3.1
Postoperative bleeding 1 0 1 1
Intra-abdominal abscess 1 0 1 1
Urine infection 0 1 1 1
Pancreatitis 0 1 1 1
Pulmonary embolism 0 1 1 1
Neutropenia 0 1 1 1
4.Discussion
Patients with locally advanced gastrointestinal carcinomas
are at high risk for recurrence. Locoregional recurrences
are usually detected at the resection site and the closest
peritoneal surfaces [11]. Cancer emboli from traumatized
interstitial tissues, severed lymphatic vessels, and venous
blood loss implant adherently at the resection site and in
abraded peritoneal surfaces. Platelets, polymorphonuclear
cells, and monocytes inﬁltrate the ﬁbrinous exudate that
accumulates during wound healing. Growth factors are
released to stimulate ﬁbroblast proliferation and local colla-
gen production. Growth factors modulating wound healing
promote cancer proliferation at the site of wound healing.
This is particularly true for tumors located in narrow limits
of resection. Cancer emboli grow rapidly and give rise
to detectable tumors within 2-3 years after initial surgical
operation [11].
Numerous publications for pseudomyxoma peritonei
[12], colorectal cancer [9], gastric cancer [13], peritoneal
mesothelioma [14], and ovarian cancer [15]h a v es h o w n
that microscopic residual tumor after cytoreductive surgery
combined with intraperitoneal chemotherapy in peritoneal
malignancy may be completely eradicated. The success
of the treatment mainly depends on the completeness of
cytoreductive surgery and on the extent of the peritoneal
malignancy [16]. Intraperitoneal chemotherapy is eﬀective
on tumor emboli that are less than 2-3mm in their largest
diameter. The peritoneal-plasma barrier has the property of
delaying the absorption of macromolecular substances to
the systemic circulation [17]. Most of the cytotoxic drugs
used for intraperitoneal administration are macromolecular
substances. The drugs instilled intraperitoneally act longer
and intensely at the peritoneal surfaces where cancer emboli
are entrapped [18]. The cytotoxic eﬀect is enhanced by heat
[19].
Three of the most potent cytotoxic agents for gastroin-
testinal carcinomas are 5-FU, mitomycin-C and oxaliplatin.
All have been successfully used in colorectal cancer with
peritoneal carcinomatosis [9, 10, 13]. Mitomycin-C, and
oxaliplatin are non-cell-speciﬁc drugs and may be used
during HIPEC [20]. 5-FU is a chemotherapeutic drug that
acts on G2 phase of the cell cycle and can be used only in
EPIC [20].
The most frequent and serious complication was anas-
tomotic leak (8.2%). The incidence was higher than
the 5% postoperative leaks reported in common elective
surgery [21]. Anastomotic healing is adversely inﬂuenced
by mitomycin-C [22]. Local hyperthermia has no adverse
eﬀect on anastomotic healing [23]. It is well known that
patients receiving intraperitoneal chemotherapy are prone
to infections, abscess formation, sepsis or wound dehiscence
[24]. Although no wound dehiscence was observed, various
infections were quitefrequent,andas a consequencethehigh
incidence of postoperative complications is easily explained.
EPIC, but not HIPEC, was found to be related to the
increased morbidity, but it was not shown to be a prognostic
indicator. Probably, the rapid infusion of the cytotoxic drugs
into the peritoneal cavity has a negative eﬀect on the recently
performed anastomosis, which may be another explanation
for the anastomotic failures and the enterocutaneousﬁstulas.
Anotherexplanationaboutthehighrateofanastomoticleaks
after EPIC is that the sutures of th ed i g e s t i v et r a c ka r eb a t h e d
for5consecutivedaysinaliquidofchemotherapythatmakes
them vulnerable [25]. The respiratory complications were
also frequent (8.2%) and this has been reported by others
[24].
Toxicity of intraperitoneal chemotherapy is very rare
and mild if one drug is used for perfusion [24, 26].
The slowly absorbed cytotoxic drugs do not show high
concentrations in the systemic circulation and cannot easily
produce systemic side eﬀects [18]. From this point of
view, intraperitoneal chemotherapy seems to be superior to
systemic chemotherapy. Only one patient in the EPIC group
was recorded with mild neutropenia that did not require
special treatment. With intraperitoneal chemotherapy renal
toxicity is also avoided with close monitoring of the diuresis
[19]. A very rare complication attributed to intraperitoneal
chemotherapy is mild pancreatitis which was recorded in
only one patient [27].ISRN Surgery 5
The most optimistic report about the overall 5-year sur-
vival rate recorded 60% and 56% for colon and rectal cancer,
respectively [28]. The diﬀerence in survival between the two
groups is signiﬁcant and may be due to either the diﬀerence
inthedegr eeofdiﬀerentiationorthe routeofintraperitoneal
chemotherapy (intraoperative versus postoperative) which
has not been clariﬁed. Similar, butnot statistically signiﬁcant
diﬀerence in overall survival has been reported for colorectal
cancer with peritoneal carcinomatosis [25]. In this paper
the HIPEC group had better survival than the EPIC group.
Although the 5-year followup has not been completed, no
death related to cancer recurrence has been recorded in
the HIPEC-group. Intraperitoneal chemotherapy has been
shown to be related to survival, but it has not been proved
to inﬂuence survival independently. However, it appears to
play a signiﬁcant role in the development of recurrence, as
has been shown by multivariate analysis. It is of signiﬁcant
importance that the number of locoregional recurrences is
very small. No patient in the HIPEC-group get 4 patients
in the EPIC group developed locoregional recurrences. It
is important to note that signiﬁcant diﬀerence in the rate
of recurrence has been documented for colorectal cancer
with peritoneal carcinomatosis [25]. Patients that received
EPIC developed recurrence more frequently than those that
received HIPEC.
5.Conclusions
Although the number of included patients is small and fur-
ther study is required, the use of intraperitoneal chemother-
apy in the treatment of locally advanced colorectal cancer
appears to play a signiﬁcant role in reducing the incidence
of recurrences. HIPEC seems to be more eﬀective than EPIC.
The survival is higher, and the number of recurrences is
smaller with the use of HIPEC.
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